404 related articles for article (PubMed ID: 12126149)
1. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.
Koenig A; Bianco SR; Fosmire S; Wojcieszyn J; Modiano JF
Vet Pathol; 2002 Jul; 39(4):458-72. PubMed ID: 12126149
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors.
Levine RA; Forest T; Smith C
Vet Pathol; 2002 May; 39(3):372-8. PubMed ID: 12014501
[TBL] [Abstract][Full Text] [Related]
3. Functional loss of p21/Waf-1 in a case of benign canine multicentric melanoma.
Ritt MG; Wojcieszyn J; Modiano JF
Vet Pathol; 1998 Mar; 35(2):94-101. PubMed ID: 9539362
[TBL] [Abstract][Full Text] [Related]
4. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of p53, PTEN, Rb, and p16 in canine osteosarcoma using tissue microarray.
Russell DS; Jaworski L; Kisseberth WC
J Vet Diagn Invest; 2018 Jul; 30(4):504-509. PubMed ID: 29629647
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines.
Levine RA; Fleischli MA
Vet Pathol; 2000 Jan; 37(1):54-61. PubMed ID: 10643981
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of the Wnt/beta-catenin signaling pathway in canine cutaneous melanotic tumor.
Han JI; Kim DY; Na KJ
Vet Pathol; 2010 Mar; 47(2):285-91. PubMed ID: 20139375
[TBL] [Abstract][Full Text] [Related]
8. The significance of p53 and retinoblastoma pathways in canine hemangiosarcoma.
Yonemaru K; Sakai H; Murakami M; Kodama A; Mori T; Yanai T; Maruo K; Masegi T
J Vet Med Sci; 2007 Mar; 69(3):271-8. PubMed ID: 17409643
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors.
Mawrin C; Kirches E; Boltze C; Dietzmann K; Roessner A; Schneider-Stock R
Virchows Arch; 2002 Jun; 440(6):610-5. PubMed ID: 12070601
[TBL] [Abstract][Full Text] [Related]
10. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Tsao H; Zhang X; Fowlkes K; Haluska FG
Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
[TBL] [Abstract][Full Text] [Related]
11. Frequent genetic defects in the p16/INK4A tumor suppressor in canine cell models of breast cancer and melanoma.
Lutful Kabir FM; DeInnocentes P; Bird AC; Bird RC
In Vitro Cell Dev Biol Anim; 2021 May; 57(5):519-530. PubMed ID: 34014456
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Wang Y; Becker D
Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
[TBL] [Abstract][Full Text] [Related]
13. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
Yang G; Rajadurai A; Tsao H
J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
[TBL] [Abstract][Full Text] [Related]
14. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L
Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948
[TBL] [Abstract][Full Text] [Related]
15. Canine gastric carcinoma: immunohistochemical expression of cell cycle proteins (p53, p21, and p16) and heat shock proteins (Hsp27 and Hsp70).
Carrasco V; Canfrán S; Rodríguez-Franco F; Benito A; Sáinz A; Rodríguez-Bertos A
Vet Pathol; 2011 Jan; 48(1):322-9. PubMed ID: 20587688
[TBL] [Abstract][Full Text] [Related]
16. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
17. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
Ishii N; Maier D; Merlo A; Tada M; Sawamura Y; Diserens AC; Van Meir EG
Brain Pathol; 1999 Jul; 9(3):469-79. PubMed ID: 10416987
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
Zhou XP; Gimm O; Hampel H; Niemann T; Walker MJ; Eng C
Am J Pathol; 2000 Oct; 157(4):1123-8. PubMed ID: 11021816
[TBL] [Abstract][Full Text] [Related]
19. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
